COST-UTILITY ANALYSIS OF NEOADJUVANT PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY HER-2 POSITIVE BREAST CANCER

被引：0
|
作者：
Ignatyeva, V [1 ]
Khachatryan, G. [1 ]
机构：
[1] Russian Presidential Acad Natl Econ & Publ Adm, Moscow, Russia
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN173
引用
收藏
页码：A739 / A740
页数：2
相关论文
共 50 条
  • [21] Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer
    Overmoyer, Beth
    Regan, Meredith
    Hu, Jiani
    Nakhlis, Faina
    Dominici, Laura
    Lin, Nancy U.
    Freedman, Rachel
    Morganstern, Daniel E.
    Partridge, Ann H.
    Schlosnagle, Emily J.
    Hirshfield-Bartek, Judi
    Bellon, Jennifer
    Morikawa, Aki
    Harrison, Beth T.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
  • [22] Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial
    Gianni, L.
    Eiermann, W.
    Semiglazov, V
    Manikhas, G. M.
    Lluch, A.
    Tjulandin, S.
    Feyereislova, A.
    Valagussa, P.
    Baselga, J.
    CANCER RESEARCH, 2009, 69 (02) : 70S - 71S
  • [23] Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)
    Shao, Z.
    Pang, D.
    Yang, H.
    Li, W.
    Wang, S.
    Cui, S.
    Liao, N.
    Wang, Y.
    Wang, C.
    Chang, Y-C
    Wang, H.
    Kang, S. Y.
    Jiang, Z.
    Li, J.
    Zhou, J.
    Althaus, B.
    Mao, Y.
    Eng-Wong, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [24] COST-UTILITY ANALYSIS OF ADJUVANT TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB IN PATIENTS WITH HER2+EARLY BREAST CANCER WITH RESIDUAL INVASIVE DISEASE AFTER NEOADJUVANT THERAPY IN SPAIN
    Colomer, R.
    Arroyo, I
    Costa-Samarra, J.
    Gallego, T.
    VALUE IN HEALTH, 2020, 23 : S442 - S442
  • [25] Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
    Lavasani, Sayeh Moazami
    Yost, Susan Elaine
    Frankel, Paul Henry
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Dan
    Menghi, Francesca
    Liu, Edison T.
    Yeon, Christina Haeyoung
    Yuan, Yuan
    Waisman, James Ross
    Somlo, George
    Mortimer, Joanne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [27] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [28] Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Ferraro, Emanuela
    Singh, Jasmeet
    Patil, Sujata
    Razavi, Pedram
    Modi, Shanu
    Chandarlapaty, Sarat
    Barrio, Andrea, V
    Malani, Rachna
    Mellinghoff, Ingo K.
    Boire, Adrienne
    Wen, Hannah Y.
    Brogi, Edi
    Seidman, Andrew D.
    Norton, Larry
    Robson, Mark E.
    Dang, Chau T.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [29] Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Emanuela Ferraro
    Jasmeet Singh
    Sujata Patil
    Pedram Razavi
    Shanu Modi
    Sarat Chandarlapaty
    Andrea V. Barrio
    Rachna Malani
    Ingo K. Mellinghoff
    Adrienne Boire
    Hannah Y. Wen
    Edi Brogi
    Andrew D. Seidman
    Larry Norton
    Mark E. Robson
    Chau T. Dang
    npj Breast Cancer, 8
  • [30] BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
    Dang, Chau
    Ewer, Michael S.
    Delaloge, Suzette
    Ferrero, Jean-Marc
    Colomer, Ramon
    de la Cruz-Merino, Luis
    Werner, Theresa L.
    Dadswell, Katherine
    Verrill, Mark
    Eiger, Daniel
    Sarkar, Sriparna
    de Haas, Sanne Lysbet
    Restuccia, Eleonora
    Swain, Sandra M.
    CANCERS, 2022, 14 (11)
12345